• Eiji Hirakawa, Satoshi Ibara, Takuya Tokuhisa, Sayuri Hiwatashi, Yoshihiro Hayashida, Yoshinobu Maede, Takako Matsui, Yusuke Nakazawa, Takeshi Inoue, and Yuichi Kodaira.
• Division of Neonatology, Perinatal Medical Center, Kagoshima City Hospital, Kagoshima, Japan. nicuhirakawa@gmail.com
• Pediatr Int. 2013 Jun 1;55(3):e70-2.

AbstractSepsis caused by group B streptococcus has been well controlled with aminobenzylpenicillin, but the incidence of Escherichia coli sepsis has increased in proportion. E. coli is a Gram-negative bacillus associated with poor prognosis due to the release of endotoxins. Conventional treatment with antibiotics alone may not be sufficient because the inflammatory response exacerbates the unstable hemodynamic status. Polymyxin B hemoperfusion has been established as a treatment option for septic shock in adults. Polymyxin B hemoperfusion adsorbs endotoxins and cannabinoids such as anandamide and 2-arachidonoylglycerol. Reported herein is a case of severe septic shock induced by E. coli. The concomitant use of polymyxin B hemoperfusion rapidly reduced the requirement for catecholamines and the patient was discharged without short-term neurological or respiratory sequelae. It is suggested that polymyxin B hemoperfusion might be an innovative therapy for severe sepsis, and could improve outcome.© 2013 The Authors. Pediatrics International © 2013 Japan Pediatric Society.

27 keywords...

hide…